Evaluation of a serum lung cancer biomarker panel

Biomarker Insights

Volumn 13, Issue , 2018, Pages

  Mazzone, Peter J ^a   Wang, Xiao Feng ^a   Han, Xiaozhen ^a   Choi, Humberto ^a   Seeley, Meredith ^a   Scherer, Richard ^b   Doseeva, Victoria ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b 20/20 GeneSystems ^*  (United States)

Author keywords

Carbohydrate antigen 125; Carcinoembryonic antigen; Cytokeratin 19 fragment 21 1; Hepatocyte growth factor; New York esophageal cancer 1 antibody

Indexed keywords

ANTIBODY NEW YORK ESOPHAGEAL CANCER 1; AUTOANTIBODY; BIOLOGICAL MARKER; CANCER ANTIBODY; CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; SCATTER FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD BANK; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER RISK; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; IMMUNOASSAY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 85041596912     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.1177/1177271917751608     Document Type: Article

References (15)

1. Pennello GA. Analytical and clinical evaluation of biomarkers assays: when are biomarkers ready for prime time? Clin Trials. 2013;10:666-676.
2. Silvestri GA, Vachani A, Whitney D, et al; AEGIS Study Team. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med. 2015;373:243-251.
3. Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, Robertson JF. Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer. 2014;83:51-55.
4. Vachani A, Hammoud Z, Springmeyer S, et al. Clinical utility of a plasma protein classifier for indeterminate lung nodules. Lung. 2015;193:1023-1027.
5. Doseeva V, Colpitts T, Gao G, Woodcock J, Knezevic V. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. J Transl Med. 2015;13:55.
6. Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT, Landreneau RJ. The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg. 1998;66:1915-1918.
7. Tsuji T, Sakamori Y, Ozasa H, et al. Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer. Oncotarget. 2017;8: 71805-71816.
8. Bishop JC, Dunstan FD, Nix BJ, Reynolds TM, Swift A. All MoMs are not equal: some statistical properties associated with reporting results in the form of multiples of the median. Am J Hum Genet. 1993;52:425-430.
9. Breiman L. Random forests. Machine learning. 2001;45:5-32.
10. Taylor JM, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res. 2008;14:5977-5983.
11. Molina R, Marrades RM, Auge JM, et al. Assessment of a combined panel of six serum tumor markers for lung cancer. Am J Respir Crit Care Med. 2016;193: 427-437.
12. Daly S, Rinewalt D, Fhied C, et al. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol. 2013;8:31-36.
13. Macdonald IK, Murray A, Healey GF, et al. Application of a high throughput method of biomarker discovery to improvement of the EarlyCDT®-Lung test. PLoS ONE. 2012;7:e51002. doi:10.1371/journal.pone.0051002.
14. Pepe MS, Janes H, Li CI, Bossuyt PM, Feng Z, Hilden J. Early-phase studies of biomarkers: what target sensitivity and specificity values might confer clinical utility? Clin Chem. 2016;62:737-742.
15. Aberle DR, Adams AM, Berg CD, et al; The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.